carbamates has been researched along with rivastigmine in 253 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 45 (17.79) | 18.2507 |
| 2000's | 205 (81.03) | 29.6817 |
| 2010's | 2 (0.79) | 24.3611 |
| 2020's | 1 (0.40) | 2.80 |
| Authors | Studies |
|---|---|
| Boddeke, H; Enz, A; Gray, J; Spiegel, R | 1 |
| Mizukawa, K; Mori, A; Ogawa, N; Tanaka, K | 1 |
| Hariguchi, S; Niigawa, H; Nishimura, T; Takeda, M; Tanimukai, S | 1 |
| Chorev, M; Enz, A; Razin, M; Weinstock, M | 1 |
| Asanuma, M; Kondo, Y; Mizukawa, K; Mori, A; Nishibayashi, S; Ogawa, N; Tanaka, K | 1 |
| Amstutz, R; Boddeke, H; Enz, A; Gmelin, G; Malanowski, J | 1 |
| Morimoto, T; Sakaki, T; Tominaga, M; Tsujimoto, S | 1 |
| Gray, J; Hatzinger, M; Hemmeter, U; Holsboer-Trachsler, E; Kocher, R; Müller, J; Spiegel, R; Stohler, R | 1 |
| Anand, R; Cutler, NR; Hartman, RD; Irwin, P; Sramek, JJ; Wardle, TS | 1 |
| Palacios, JM | 1 |
| Schneider, LS | 2 |
| Demura, N; Fukaya, H; Iimura, A; Ohara, T; Seno, N; Tanaka, K | 1 |
| Fukaya, H; Itanaka, K; Ohara, T; Seno, N | 1 |
| Honma, A | 1 |
| Bass, R; Chen, Y; Shohami, E; Weinstock, M | 1 |
| Chen, Y; Constantini, S; Shohami, E; Weinstock, M | 1 |
| Cutler, NR; Enz, A; Hourani, J; Jhee, SS; Mancione, L; Polinsky, RJ; Sramek, JJ; Zolnouni, P | 1 |
| Habucky, K; Tse, FL | 1 |
| Laplanche, R; Tse, FL | 1 |
| Noble, S; Spencer, CM | 1 |
| Brefel-Courbon, C; Freslon, JL; Lazartigues, E; Montastruc, JL; Pelat, M; Rascol, O; Tellioglu, T; Tran, MA | 1 |
| Lacomblez, L | 1 |
| Derquesné, C | 1 |
| Jansen, RW; Olde Rikkert, MG | 1 |
| Agid, Y; Anand, R; Cicin-Sain, A; Dal-Bianco, P; Gauthier, S; Gharabawi, M; Hartman, R; Rösler, M; Stähelin, HB | 1 |
| Bayer, T | 1 |
| Berger, A | 1 |
| Anand, R; Forette, F; Gharabawi, G | 1 |
| Dom, R; Lemière, J; Van Gool, D | 1 |
| Bentham, P; Gray, R; Raftery, J; Sellwood, E | 1 |
| Ballard, TM; McAllister, KH | 1 |
| de Haan, RJ; Vermeulen, M | 1 |
| Kosasa, T; Kuriya, Y; Matsui, K; Yamanishi, Y | 2 |
| Harvey, RJ; Rossor, MN; Selai, CE; Trimble, MR | 1 |
| Elferink, AJ; Storosum, JG; van Zwieten-Boot, BJ | 1 |
| Hébert, M | 1 |
| Ebert, MH; Enz, A; Johnson, B; Kennedy, JS; Laplanche, R; Loosen, P; Mancione, LC; Parris, WC; Polinsky, RJ; Schmidt, D | 1 |
| Kosasa, T; Kuriya, Y; Yamanishi, Y | 1 |
| Bejar, C; Wang, RH; Weinstock, M | 2 |
| McMillan, H | 1 |
| Burns, A; Page, S; Russell, E | 1 |
| Jann, MW | 1 |
| Sim, A | 1 |
| Böhnke, M; Garweg, JG; Goldblum, D | 1 |
| Bullock, R; Howard, R; Jones, R; Passmore, P; Wilkinson, D | 1 |
| Anand, R; Grossberg, GT; Messina, JC; Stahelin, HB; Veach, J | 1 |
| Berger, M; Braus, D; Gattaz, WF; Heuser, I; Riemann, D; Schredl, M; Weber, B | 1 |
| Birks, J; Iakovidou, V; Tsolaki, M | 2 |
| Anand, R; Hartman, R; Kumar, V; Messina, J; Veach, J | 1 |
| Cagiano, R; Coluccia, A; Cuomo, V; Gaetani, S; Kendrick, KM; Pietra, C; Tattoli, M; Trabace, L | 1 |
| Byrne, EJ; Grace, JB; McKeith, IG; Perry, EK; Stevens, T; Walker, Z; Wilkinson, D | 1 |
| Gnanasakthy, A; Hauber, AB; Mauskopf, JA | 1 |
| Baik, J; Han, IW; Koo, MS; Kwak, YT | 1 |
| Bala, MV; Gnanasakthy, A; Hauber, AB; Mauskopf, JA; Richter, A; Snyder, EH | 1 |
| Babic, T; Banfic, L; Barisic, N; Jelincic, Z; Papa, J; Zurak, N | 1 |
| Stahl, SM | 2 |
| Anand, R; Farlow, M; Hartman, R; Messina, J; Veach, J | 1 |
| Dronfield, S; Egan, K; Green, AR; Marsden, CA | 1 |
| Grace, JB; McKeith, IG; Walker, MP | 1 |
| Anand, R; Cicin-Sain, A; Del Ser, T; Ferrara, R; McKeith, I; Spiegel, R | 1 |
| Fisher, A | 1 |
| Cummings, JL | 1 |
| Anand, R; Cicin-Sain, A; Del Ser, T; Emre, M; Ferrara, R; McKeith, I; Spano, P; Spiegel, R; Wesnes, K | 1 |
| Bailey, PA; Baladi, JF; Black, S; Bouchard, RW; Farcnik, KD; Gauthier, S; Kertesz, A; Mohr, E; Robillard, A | 1 |
| Giacobini, E | 1 |
| Fischer, P | 1 |
| Grutzendler, J; Morris, JC | 1 |
| Hjelmstad, GO; Linkins, KW; Lloyd, JR; Strausbaugh, HJ | 1 |
| Hogan, DB; Patterson, C | 1 |
| Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J | 1 |
| Kosasa, T; Kuriya, Y; Ogura, H; Yamanishi, Y | 1 |
| Lemstra, AW; Richard, E; van Gool, WA; Walstra, GJ | 1 |
| Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N | 2 |
| Goa, KL; Lamb, HM | 1 |
| Desai, A; Grossberg, G | 1 |
| Adler, G; Brassen, S | 2 |
| Kumar, V | 1 |
| Farlow, MR | 3 |
| Antonello, RM; Cazzato, G; Moretti, R; Torre, P | 1 |
| Hake, AM | 1 |
| Cagiano, R; Cassano, T; Cuomo, V; Kendrick, KM; Pietra, C; Steardo, L; Tattoli, M; Trabace, L | 1 |
| Butler, S; Byrne, EJ; Daniel, S; Grace, J; McKeith, IG; Shankar, KK; Stevens, T; Waite, J; Walker, Z; Wilkinson, D; Woolford, J | 1 |
| Lampley-Dallas, VT | 1 |
| Gavrilova, SI; Zharikov, GA | 1 |
| Deleu, D | 1 |
| Slagle, MA | 1 |
| Smith, DJ; Yukhnevich, S | 1 |
| Cutler, NR; Gobburu, JV; Jhee, SS; Lesko, L; Sramek, JJ; Tammara, V; Yuan, R | 1 |
| Amici, S; Antognelli, C; Gallai, V; Lanari, A; Parnetti, L; Romani, R | 1 |
| García, MJ; Martínez-Martos, JM; Mayas, MD; Ramírez, M; Ramírez-Expósito, MJ; Robert-Baudouy, J | 1 |
| Alva, G; Anand, R; Carreon, D; Fallon, JH; Fleming, K; Hartman, R; Keator, D; Messina, J; Potkin, SG; Wu, JC | 1 |
| Winblad, B | 1 |
| Sternon, J; Ventura, M | 1 |
| Camarda, R; Lopez, G; Mannino, M; Monastero, R | 1 |
| Caffarra, P; Godani, M; Majer, S; Paolello, P | 1 |
| Luce, AK; McKeith, IG; Reading, PJ | 1 |
| Schorer-Apelbaum, D; Wang, RH; Weinstock, M | 1 |
| Byrne, EJ; Collins, CC; Maclean, LE | 1 |
| Gasser, T; Schreiter Gasser, U | 1 |
| Richard, E; van Campen, J; van Gool, WA; Vissers, E; Walstra, GJ | 1 |
| Ballard, CG | 1 |
| Gasser, T; Gasser, US | 1 |
| Borioni, A; Del Giudice, MR; Ferretti, R; Gatta, F; Lorenzini, P; Meneguz, A; Mustazza, C; Volpe, MT | 1 |
| Barcikowska, M; Bilikiewicz, A; Bilińska, M; Gabryelewicz, T; Ochudło, S; Opala, G; Paradowski, B; Parnowski, T; Pfeffer, A; Podemski, R; Puzyński, S; Sołtys, K; Łapin, J | 1 |
| Bar-On, P; Dvir, H; Enz, A; Harel, M; Millard, CB; Silman, I; Sussman, JL | 1 |
| Lechner, A; Petrovic, K; Schmidt, R | 1 |
| Anand, R; Cicin-Sain, A; Del Ser, T; Emre, M; Ferrara, R; McKeith, IG; Spano, PF; Spiegel, R; Wesnes, KA | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Bullock, R; Connolly, C | 1 |
| Forbes, KE; Gemmell, HG; Murray, AD; Pestell, SJ; Shanks, MF; Staff, RT; Venneri, A | 1 |
| Cutler, NR; Hossain, M; Jhee, SS; McDonald, C; Pommier, F; Sedek, G; Shiovitz, T | 1 |
| Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O | 1 |
| Andreae, D; Grohmann, R; Heinze, M | 1 |
| Alvarez, AM; Andrade, FC; Avila, R; Bottino, CM; Bustamante, SE; Camargo, CH; Carvalho, IA; Hototian, SR; Saffi, F; Zukauskas, PR | 1 |
| Dourish, J; Walsh, E | 1 |
| Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M | 1 |
| Klein, C; Rabey, JM; Werber, AE | 1 |
| Anand, R; Graham, S; Hartman, R; Morganroth, J | 1 |
| Bullock, R | 1 |
| Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B | 1 |
| Auriacombe, S; Loria-Kanza, Y; Pere, JJ; Vellas, B | 1 |
| Robert, P | 1 |
| Blount, PJ; McDeavitt, JT; Nguyen, CD | 1 |
| Cutler, NR; Enz, A; Giacobini, E; Spiegel, R; Veroff, AE | 1 |
| Bellucci, A; Casamenti, F; Costagli, C; Pepeu, G; Scali, C; Schmidt, B | 1 |
| Demers, L; Momoli, F; Moride, Y; Oremus, M; Perrault, A; Shukla, V; Wolfson, C | 1 |
| Rösler, M | 1 |
| Inglis, F | 2 |
| Jann, MW; Shirley, KL; Small, GW | 1 |
| Darcourt, J; Ebmeier, K; Koulibaly, M; Mariani, G; Migneco, O; Nobili, F; Pupi, A; Robert, PH; Rodriguez, G; Vitali, P | 1 |
| Daniele, A; Di Lazzaro, V; Marra, C; Masullo, C; Oliviero, A; Pilato, F; Profice, P; Rothwell, JC; Saturno, E; Tonali, PA | 1 |
| Ott, BR | 1 |
| Anand, R; Danyluk, J; Doraiswamy, PM; Hartman, RD; Krishnan, KR; Sohn, H; Veach, J | 1 |
| Anand, R; Grossberg, G; Hartman, R; Potki, SG; Veach, J | 1 |
| Almkvist, O; Darreh-Shori, T; Garlind, A; Guan, ZZ; Hellström-Lindahl, E; Nordberg, A; Soreq, H; Strandberg, B; Svensson, AL | 1 |
| Ballmaier, M; Casamenti, F; Mazzoncini, R; Pepeu, G; Scali, C; Spano, PF; Zoli, M | 1 |
| Bullock, R; Cameron, A | 1 |
| Kim, JM; Shin, IS; Yoon, JS | 1 |
| Anderson, DM; Hoehns, JD; Taylor, AM; Tobert, DG | 1 |
| Howard, R; Sauer, J | 1 |
| Castro, A; Martinez, A | 1 |
| Barberger-Gateau, P; Bourdeix, I; Dartigues, JF; Goulley, F; Péré, JJ | 1 |
| Henn, FA; Lederbogen, F; Sartorius, A; Zink, M | 1 |
| Antonello, RM; Bava, A; Cazzato, G; Moretti, R; Torre, P | 2 |
| Barkhof, F; Rombouts, SA; Scheltens, P; Van Meel, CS | 1 |
| McRae, TD; Schwam, EM | 1 |
| Tang, XC; Zhao, Q | 1 |
| Kobal, J; Mesec, A; Pirtosek, Z; Rot, U; Sever, A | 1 |
| Järvenpää, T; Kaasinen, V; Kurki, T; Någren, K; Oikonen, V; Rinne, JO; Roivainen, A; Yu, M | 1 |
| Blesa, R; Cardellach, F; Casademont, J; Miró, O; Rodriguez-Santiago, B; Viedma, P | 1 |
| Kamei, H; Nabeshima, T; Noda, Y | 1 |
| Frigola, R; Pommier, F | 1 |
| Andrews, C; Erkinjuntti, T; Lane, R; Skoog, I | 2 |
| André, G; Pere, JJ; Rigaud, AS; Touchon, J; Vellas, B | 1 |
| Amici, S; Andreasen, N; Antognelli, C; Blennow, K; Davidsson, P; Gallai, V; Lanari, A; Minthon, L; Parnetti, L; Pottel, H; Romani, C | 1 |
| Hoefnagels, WH; Horstink, MW; Scheepmaker, AJ; Strijks, FE | 1 |
| Almkvist, O; Blennow, K; Hellström-Lindahl, E; Nordberg, A; Stefanova, E | 1 |
| Hartmann, S; Möbius, HJ | 1 |
| Berghmans, RL; Huizing, AR; Verhey, FR; Widdershoven, GA | 1 |
| Adler, G; Berger, FM; Calabrese, P; Frölich, L; Gertz, HJ; Hampel, H; Haupt, M; Jendroska, K; Kohler, J; Mielke, R; Paulus, HJ; Pilartz, H; Riepe, MW; Zedlick, D | 1 |
| Farlow, M | 1 |
| Albuquerque, EX; Christner, C; Fehrenbacher, A; Höffle, A; Jostock, R; Lübbert, H; Ludwig, J; Maelicke, A; Pereira, EF; Radina, M; Samochocki, M; Ullmer, C; Zerlin, M | 1 |
| Fogelson, N; Giladi, N; Kogan, E; Korczyn, AD; Neufeld, MY; Shabtai, H | 1 |
| Retz, W; Retz-Junginger, P; Rösler, M; Supprian, T; Wobrock, T | 1 |
| Thacker, PD | 1 |
| Dhondt, AD; Moerkens, RM | 1 |
| Mol, JA | 1 |
| Gabelli, C | 1 |
| Gandelman-Marton, R; Klein, C; Rabey, JM; Werber, EA | 1 |
| Akkawi, N; Bordonali, T; Borroni, B; Di Luca, M; Padovani, A; Pettenati, C | 1 |
| Dautzenberg, PL; Oudejans, I; Samson, MM; Wouters, CJ | 1 |
| Barnaby, L; Gibson, RC | 1 |
| Farlow, M; Koumaras, B; Mirski, D; Potkin, S; Veach, J | 1 |
| Bianchetti, A; Rozzini, R; Trabucchi, M | 1 |
| Gray, R | 1 |
| Gill, MA; Nazarians, A; Williams, BR | 1 |
| Capuano, A; Della Marca, G; Paciello, N; Restuccia, D; Rubino, M; Tonali, P; Valeriani, M; Vollono, C | 1 |
| Burns, A; Pettit, T; Wild, R | 1 |
| Alagiakrishnan, K; Robertson, D; Sclater, A | 1 |
| Doody, RS | 1 |
| Matthews, PM; Palace, J; Parry, AM; Scott, RB; Smith, S | 1 |
| Butler, R; Prabhakaran, P; Warner, J | 1 |
| Bonelli, RM | 1 |
| Pan, Y; Wang, X; Xu, X | 1 |
| Rakonczay, Z | 1 |
| Fuchsberger, T; Hampel, H; Möller, HJ | 1 |
| Baezner, H; Daffertshofer, M | 1 |
| Bochynska, A; Jakubowska, T; Jarosz, H; Jedrzejczak, T; Lojkowska, W; Minc, S; Ryglewicz, D | 1 |
| Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H | 1 |
| André, G; Loria-Kanza, Y; Pere, JJ; Rigaud, AS; Touchon, J; Vellas, B | 1 |
| Alhainen, K | 1 |
| Kaufer, DI | 2 |
| Bullock, R; Emre, M; Farlow, MR; Gauthier, S; Grossberg, GT; Potkin, SG | 1 |
| Auriacombe, S; Pere, JJ | 1 |
| Barkhof, F; Bastos Leite, AJ; Lycklama, G; Scheltens, P; van Straaten, EC | 1 |
| Adler, G; Brassen, S; Chwalek, K; Dieter, B; Teufel, M | 1 |
| Haen, E; Ibach, B | 1 |
| Alisky, JM | 1 |
| de Brito-Marques, PR; de Mello, RV; Montenegro, L | 1 |
| Bernardi, A; Pegoraro, R | 1 |
| Amaya, K; Casciano, J; Casciano, R; Chang, S; Cheng, I; Cuccia, AJ; Marin, D; Puder, KL; Snyder, EH | 1 |
| Erkinjuntti, T; Feldman, H; Gauthier, S; Rockwood, K; Román, G | 1 |
| Darreh-Shori, T; Flores-Flores, C; Guan, ZZ; Hellström-Lindahl, E; Nordberg, A; Soreq, H | 1 |
| Daniele, A; Di Lazzaro, V; Dileone, M; Gainotti, G; Ghirlanda, S; Marra, C; Oliviero, A; Pilato, F; Saturno, E; Tonali, PA | 1 |
| Burns, A; Quarg, P; Spiegel, R | 1 |
| Almkvist, O; Darreh-Shori, T; Nordberg, A; Spiegel, R; Stefanova, E | 1 |
| Feldman, H; Ferris, S; Hermann, N; Lane, R; Mancione, L; Mesenbrink, P; Scarpini, E; Scheltens, P; Tekin, S | 1 |
| Arcona, S; Mirski, D; Powers, C; Rabinowicz, AL; Shin, H; Suh, DC; Thomas, SK | 1 |
| Ferrara, R; McKeith, IG; Perry, E; Wesnes, KA | 1 |
| Rioux, S | 1 |
| Aimonovitch, M; Buchanan, T; Chez, MG; Mrazek, S; Tremb, RJ | 1 |
| Liang, YQ; Tang, XC | 1 |
| Hossain, M; Lee, L; Sedek, G; Wang, Y | 1 |
| Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M | 1 |
| Amenta, F; Di Tullio, MA; Tayebati, SK | 1 |
| Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E | 1 |
| Prasher, VP | 1 |
| Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T | 1 |
| Birks, J; Evans, JG; Wilcock, G | 1 |
| van Dyck, CH | 1 |
| Dautzenberg, PL; Loonen, AJ; Mulder, LJ; Olde Rikkert, MG; Wouters, CJ | 1 |
| Finkel, SI | 1 |
| Boelaarts, L; de Jonghe, JF; Hovinga, IM; Kalisvaart, CJ; Kat, MG | 1 |
| Driguès, N; Sagi, Y; Youdim, MB | 1 |
| Ashani, Y; Groner, E; Herzig, Y; Schorer-Apelbaum, D; Sterling, J; Weinstock, M | 1 |
| Dantoine, T; Debord, J; Laubarie, C | 1 |
| Connors, SL; Du, S; Ferreira, JP; Kochendörfer, U; Martin, AN; Slepnev, VI; Verheijen, JC; Wiig, KA | 1 |
| Imramovsky, A; Jampilek, J; Monreal-Ferriz, J; Pauk, K; Stepankova, S; Vanco, J; Vinsova, J | 1 |
| Gluck, N; Mouhadeb, O; Shifrin, H; Varol, C; Weinstock, M | 1 |
| Allarà, M; Bartolini, M; Belluti, F; Bisi, A; Gobbi, S; Kostrzewa, M; Ligresti, A; Montanari, S; Naldi, M; Rampa, A; Rivara, S; Scalvini, L | 1 |
58 review(s) available for carbamates and rivastigmine
| Article | Year |
|---|---|
Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors.
Topics: Animals; Brain; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1994 |
Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Carbamates; Cats; Cholinesterase Inhibitors; Hemodynamics; Hippocampus; Humans; Motor Activity; Nerve Tissue Proteins; Phenylcarbamates; Rats; Rivastigmine; Saimiri; Salivation | 1993 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 1996 |
[Therapeutic agents for Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Neuropeptides; Phenylcarbamates; Piperidines; Receptor, Muscarinic M1; Receptors, Muscarinic; Rivastigmine; Spiro Compounds; Tacrine | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 1998 |
Rivastigmine. A review of its use in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Interactions; Humans; Learning; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Sleep; Substance-Related Disorders | 1998 |
Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Chemical and Drug Induced Liver Injury; Cholinergic Agents; Cholinergic Fibers; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, Cholinergic; Receptors, Muscarinic; Receptors, Nicotinic; Rivastigmine; Tacrine | 1999 |
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-beta; Migraine Disorders; Multiple Sclerosis; Nervous System Diseases; Netherlands; Neuroprotective Agents; Outcome Assessment, Health Care; Phenylcarbamates; Riluzole; Rivastigmine; Sumatriptan; Vasoconstrictor Agents | 1999 |
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Multicenter Studies as Topic; Neuroprotective Agents; Phenylcarbamates; Rats; Rivastigmine | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Rivastigmine; Severity of Illness Index | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2000 |
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cost Savings; Economics, Pharmaceutical; Female; Health Care Costs; Humans; Institutionalization; Intelligence Tests; Male; Neuroprotective Agents; Phenylcarbamates; Probability; Proportional Hazards Models; Rivastigmine; Severity of Illness Index; Survival Rate | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index | 2000 |
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Carbamates; Cheirogaleidae; Disease Models, Animal; Humans; Muscarinic Agonists; Neuroprotective Agents; Phenylcarbamates; Piperidines; Receptor, Muscarinic M1; Receptors, Muscarinic; Rivastigmine; Signal Transduction; tau Proteins; Thiazoles | 2000 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 2000 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Brief review: rivastigmine, a second cholinesterase inhibitor.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2001 |
[Evaluation of the therapeutic effects in individual patients with Alzheimer disease].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Humans; Netherlands; Nootropic Agents; Phenylcarbamates; Practice Guidelines as Topic; Psychiatric Status Rating Scales; Rivastigmine; Severity of Illness Index; Social Behavior; Treatment Outcome | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Topics: Alzheimer Disease; Carbamates; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2001 |
Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Health Care Costs; Humans; Phenylcarbamates; Rivastigmine | 2001 |
Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Interactions; Humans; Neuroprotective Agents; Patient Selection; Phenylcarbamates; Rivastigmine | 2001 |
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors | 2001 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Disease Progression; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Ginkgo biloba; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Phytotherapy; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine; Trichlorfon | 2001 |
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2002 |
Understanding changes in cholinergic function: implications for treating dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibitors; Dementia; Humans; Lewy Body Disease; Mental Disorders; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2002 |
[Perspectives for drug treatment in Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dementia; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Donepezil; Humans; Indans; Lorazepam; Patient Education as Topic; Phenylcarbamates; Piperidines; Risperidone; Rivastigmine | 2002 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
Clinical use of cholinomimetic agents: a review.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Brain Injuries; Carbamates; Clinical Trials as Topic; Cytidine Diphosphate Choline; Donepezil; Female; Follow-Up Studies; Humans; Indans; Injections, Intravenous; Injury Severity Score; Male; Middle Aged; Parasympathomimetics; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Humans; Indans; Middle Aged; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2002 |
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Topics: Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2002 |
Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Humans; Nootropic Agents; Phenylcarbamates; Rivastigmine | 2002 |
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Topics: Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2002 |
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Topics: Aging; Alzheimer Disease; Biological Availability; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Half-Life; Humans; Indans; Intestinal Absorption; Liver; Phenylcarbamates; Piperidines; Protein Binding; Rivastigmine; Tacrine; Tissue Distribution | 2002 |
Medical treatment of Alzheimer's disease: past, present, and future.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Binding Sites; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Indans; Molecular Conformation; Molecular Structure; Phenylcarbamates; Piperidines; Rivastigmine; Structure-Activity Relationship; Tacrine | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost of Illness; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2002 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; tau Proteins | 2002 |
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2002 |
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Disease Progression; Economics, Pharmaceutical; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Risk Factors; Rivastigmine; Treatment Outcome | 2003 |
A review of rivastigmine: a reversible cholinesterase inhibitor.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Drug Interactions; Humans; Phenylcarbamates; Rivastigmine | 2003 |
Cholinesterase inhibitors for dementia with Lewy bodies.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2003 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2003 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phosphatidylcholines; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine; Vitamin E | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dementia; Dementia, Vascular; Donepezil; Dopamine Agents; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Meta-Analysis as Topic; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Plant Preparations; Prospective Studies; Rivastigmine; Tacrine; Time Factors | 2003 |
[Subcortical vascular encephalopathy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Brain; Carbamates; Clinical Trials as Topic; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; Gait; Humans; Indans; Magnetic Resonance Imaging; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Pilot Projects; Piperidines; Placebos; Prognosis; Risk Factors; Rivastigmine; Time Factors; Tomography, X-Ray Computed; Walking | 2003 |
Update on rivastigmine.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Rivastigmine | 2003 |
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Female; Humans; Indans; Male; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Treatment Failure; Treatment Outcome | 2003 |
Acetylcholinesterase inhibition in Alzheimer's Disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2004 |
Rivastigmine in vascular dementia.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Drug Interactions; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2004 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2004 |
What are the treatment options for patients with severe Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
Evidence-based pharmacotherapy of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Research Design; Rivastigmine | 2004 |
Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
59 trial(s) available for carbamates and rivastigmine
| Article | Year |
|---|---|
Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Male; Phenylcarbamates; Physostigmine; Placebos; Rats; Rivastigmine | 1991 |
Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man.
Topics: Adolescent; Adult; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Humans; Male; Phenylcarbamates; Rivastigmine; Sleep; Sleep, REM | 1993 |
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine | 1996 |
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Carbamates; Cerebrospinal Fluid; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine | 1998 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine | 1999 |
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Electrocardiography; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 1999 |
Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Mental Status Schedule; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Scotland; Time Factors; Treatment Failure; Treatment Outcome | 1999 |
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia, Vascular; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Risk Factors; Rivastigmine; Treatment Outcome | 2000 |
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Tolerance; Female; Humans; Lewy Body Disease; Male; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2000 |
Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Topics: Aged; Algorithms; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cognition; Cost Savings; Cost-Benefit Analysis; Disease Progression; Female; Humans; Male; Middle Aged; Models, Economic; Neuroprotective Agents; Phenylcarbamates; Proportional Hazards Models; Psychiatric Status Rating Scales; Quality-Adjusted Life Years; Rivastigmine | 2000 |
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Phenylcarbamates; Rivastigmine; Time Factors; Treatment Outcome | 2000 |
Dementia with lewy bodies: findings from an international multicentre study.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Female; Humans; Lewy Body Disease; Male; Mental Status Schedule; Middle Aged; Neurologic Examination; Neuropsychological Tests; Phenylcarbamates; Psychometrics; Reproducibility of Results; Rivastigmine | 2000 |
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Lewy Body Disease; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2000 |
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Double-Blind Method; Female; Humans; Linear Models; Male; Phenylcarbamates; Predictive Value of Tests; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Electroencephalography; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 2001 |
Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up.
Topics: Aged; Carbamates; Dementia, Vascular; Female; Follow-Up Studies; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2001 |
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Cognition; Female; Humans; Lewy Body Disease; Male; Middle Aged; Neuroprotective Agents; Parkinsonian Disorders; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2001 |
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Neuropsychological Tests; Patients; Phenylcarbamates; Rivastigmine | 2001 |
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Chemistry; Carbamates; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Radiopharmaceuticals; Rivastigmine; Tomography, Emission-Computed | 2001 |
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Stress, Psychological; Treatment Outcome | 2001 |
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Disease Progression; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Rivastigmine in outpatient services: experience of 114 neurologists in Austria.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Austria; Carbamates; Cognition; Disease Progression; Female; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Outpatients; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome | 2002 |
Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system.
Topics: Aged; Carbamates; Diagnosis, Computer-Assisted; Double-Blind Method; Female; Follow-Up Studies; Humans; Lewy Body Disease; Male; Neurology; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome | 2002 |
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cluster Analysis; Cognition; Female; Humans; Longitudinal Studies; Male; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Radiopharmaceuticals; Rivastigmine; Technetium Tc 99m Exametazime; Time Factors; Tomography, Emission-Computed, Single-Photon | 2002 |
Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Biological Availability; Carbamates; Cholinesterase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Phenylcarbamates; Rivastigmine | 2002 |
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Dementia; Drug Therapy, Combination; Female; Humans; Male; Phenylcarbamates; Risperidone; Rivastigmine; Social Behavior Disorders | 2002 |
Electrocardiographic effects of rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bradycardia; Carbamates; Cardiovascular System; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Diseases; Heart Rate; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Tachycardia | 2002 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Failure; Treatment Outcome | 2002 |
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine | 2002 |
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Double-Blind Method; Female; Humans; Male; Phenylcarbamates; Rivastigmine; Time | 2002 |
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Double-Blind Method; Humans; Middle Aged; Phenylcarbamates; Rivastigmine | 2002 |
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Attention; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Cholinesterases; Colorimetry; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; Immunoblotting; Isoenzymes; Male; Memory; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Time; Treatment Outcome; Up-Regulation | 2002 |
Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Patient Dropouts; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine | 2002 |
[Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Tolerance; Female; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index | 2002 |
Rivastigmine in subcortical vascular dementia: an open 22-month study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Behavior; Carbamates; Caregivers; Cholinesterase Inhibitors; Dementia, Vascular; Female; Follow-Up Studies; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Stress, Psychological; Treatment Outcome | 2002 |
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Female; Frontal Lobe; Humans; Indans; Magnetic Resonance Imaging; Male; Parietal Lobe; Phenylcarbamates; Piperidines; Reproducibility of Results; Rivastigmine; Temporal Lobe; Tomography, Emission-Computed | 2002 |
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Electron Transport; Female; Humans; Lymphocytes; Male; Mitochondria; Neuroprotective Agents; Phenylcarbamates; Reference Values; Rivastigmine | 2003 |
Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Hypertension; Male; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2002 |
No additional benefit of HRT on response to rivastigmine in menopausal women with AD.
Topics: Activities of Daily Living; Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Estradiol; Female; France; Hormone Replacement Therapy; Humans; Menopause; Neuropsychological Tests; Phenylcarbamates; Progesterone; Rivastigmine; Treatment Outcome | 2003 |
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Galantamine; Humans; Indans; Peptide Fragments; Phenylcarbamates; Phosphorylation; Piperidines; Rivastigmine; tau Proteins | 2002 |
Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E2; Apolipoprotein E4; Apolipoproteins E; Biomarkers; Brain; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Genotype; Glucose; Humans; Male; Middle Aged; Peptide Fragments; Phenylcarbamates; Rivastigmine; Tacrine; tau Proteins | 2003 |
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Dementia; Electroencephalography; Female; Humans; Male; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine | 2003 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Electroencephalography; Event-Related Potentials, P300; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Prospective Studies; Reaction Time; Rivastigmine; Tacrine; Treatment Outcome | 2003 |
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Carbamates; Cholesterol; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Genotype; Humans; Indans; Male; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2003 |
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Patient Dropouts; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2003 |
Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Female; Humans; Indans; Male; Nootropic Agents; Phenylcarbamates; Pilot Projects; Piperidines; Rivastigmine | 2003 |
Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine.
Topics: Adult; Carbamates; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neuronal Plasticity; Neuropsychological Tests; Phenylcarbamates; Prefrontal Cortex; Rivastigmine | 2003 |
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Aged; Alzheimer Disease; Auditory Perception; Carbamates; Cerebrovascular Circulation; Cholinesterase Inhibitors; Dementia, Vascular; Female; Frontal Lobe; Humans; Learning; Magnetic Resonance Imaging; Male; Phenylcarbamates; Rivastigmine; Temporal Lobe; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Up-Regulation | 2003 |
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Male; Parkinson Disease; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Time Factors; Treatment Outcome | 2003 |
[Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Combined Modality Therapy; Double-Blind Method; Estrogens; Female; Humans; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Placebos; Postmenopause; Progestins; Rivastigmine | 2003 |
Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Electroencephalography; Female; Humans; Indans; Male; Memory; Memory Disorders; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Theta Rhythm; Time Factors; Treatment Outcome | 2003 |
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Female; Humans; Hypertension; Male; Medical Records; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2003 |
Prediction of treatment response to rivastigmine in Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Administration Schedule; Electroencephalography; Female; Humans; Male; Memory, Short-Term; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Theta Rhythm | 2004 |
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Attention; Carbamates; Case-Control Studies; Chi-Square Distribution; Cholinesterases; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Statistics as Topic; Time Factors | 2004 |
Behavioral symptoms in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine | 2004 |
Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.
Topics: Aged; Attention; Carbamates; Disease Progression; Double-Blind Method; Female; Hallucinations; Humans; Lewy Body Disease; Male; Neuroprotective Agents; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Prospective Studies; Reaction Time; Risk Factors; Rivastigmine | 2004 |
Absorption of rivastigmine from different regions of the gastrointestinal tract in humans.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Carbamates; Colon, Ascending; Female; Half-Life; Humans; Ileum; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Male; Neuroprotective Agents; Organ Specificity; Phenylcarbamates; Rivastigmine | 2004 |
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Drug Therapy, Combination; Female; Humans; Male; Nimodipine; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome; Vasodilator Agents | 2004 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index | 2004 |
136 other study(ies) available for carbamates and rivastigmine
| Article | Year |
|---|---|
Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus.
Topics: Animals; Astrocytes; Carbamates; Cell Death; Cholinesterase Inhibitors; Gerbillinae; Glial Fibrillary Acidic Protein; Hippocampus; Hypertrophy; Ischemic Attack, Transient; Neurons; Phenylcarbamates; Pyramidal Cells; Rivastigmine | 1995 |
Effects of SDZ ENA 713, novel acetyl cholinesterase inhibitor, on learning of rats with basal forebrain lesions.
Topics: Animals; Body Weight; Carbamates; Cholinesterase Inhibitors; Electric Stimulation; Learning; Locomotion; Phenylcarbamates; Prosencephalon; Rats; Rats, Wistar; Rivastigmine | 1995 |
Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia.
Topics: Acetylcholine; Animals; Carbamates; Cholinesterase Inhibitors; Gerbillinae; Ischemic Attack, Transient; Molecular Structure; Phenylcarbamates; Receptors, Muscarinic; Rivastigmine; Synapses | 1994 |
The effect of acetylcholinesterase inhibitor (SDZ ENA 713) for r-CBF and focal cerebral ischaemia.
Topics: Acetylcholine; Animals; Brain; Brain Ischemia; Carbamates; Cats; Cerebral Infarction; Cholinesterase Inhibitors; Female; Ischemic Attack, Transient; Laser-Doppler Flowmetry; Male; Phenylcarbamates; Pia Mater; Regional Blood Flow; Rivastigmine; Vascular Resistance | 1993 |
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indans; Muscarinic Agonists; Oximes; Phenylcarbamates; Piperidines; Pyridines; Rivastigmine; Tacrine; Thiadiazoles | 1996 |
SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Brain Chemistry; Carbamates; Choline O-Acetyltransferase; Cholinergic Antagonists; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Male; Memory Disorders; Microdialysis; Parasympathetic Nervous System; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Scopolamine; Space Perception | 1997 |
Ameliorating effects of SDZ ENA 713 on age-associated decreases in learning performance and brain choline acetyltransferase activity in rats.
Topics: Aging; Animals; Biomarkers; Brain; Carbamates; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Learning Disabilities; Male; Maze Learning; Phenylcarbamates; Rats; Rats, Inbred F344; Receptors, Muscarinic; Rivastigmine | 1997 |
Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat.
Topics: Animals; Blood-Brain Barrier; Body Temperature; Brain Edema; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Head Injuries, Closed; Hippocampus; Male; Movement; Phenylcarbamates; Rats; Reflex; Rivastigmine; Scopolamine | 1998 |
Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse.
Topics: Animals; Brain Edema; Carbamates; Cholinergic Antagonists; Cholinesterase Inhibitors; Cognition Disorders; Head Injuries, Closed; Male; Maze Learning; Mecamylamine; Memory; Mice; Movement; Movement Disorders; Muscarinic Antagonists; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Scopolamine | 1998 |
Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit.
Topics: Animals; Carbamates; Cholinesterase Inhibitors; Female; Milk; Phenylcarbamates; Placenta; Pregnancy; Rabbits; Rivastigmine; Tissue Distribution | 1998 |
[Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 1998 |
Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Carbamates; Cholinesterase Inhibitors; Injections, Intravenous; Male; Phenylcarbamates; Rivastigmine; Swine; Swine, Miniature | 1998 |
Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.
Topics: Adrenergic Antagonists; Animals; Antidiuretic Hormone Receptor Antagonists; Atropine; Atropine Derivatives; Blood Pressure; Carbamates; Cardiovascular Agents; Chlorisondamine; Cholinergic Antagonists; Cholinesterase Inhibitors; Diamines; Diastole; Dose-Response Relationship, Drug; Heart Rate; Male; Phenylcarbamates; Physostigmine; Piperidines; Pirenzepine; Rats; Rats, Wistar; Rivastigmine; Systole; Tacrine | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Depression; Donepezil; Humans; Indans; Mental Disorders; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Sleep Wake Disorders; Tacrine | 1998 |
[New perspectives for Alzheimer patients: acetylcholine inhibition with Rivastigmine. Congress of the European Neurologic Society. Nice, 6 July 199].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1998 |
[Alzheimer's disease. Foreword].
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 1998 |
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Drug Approval; Europe; Female; Humans; Male; Phenylcarbamates; Rivastigmine; United States | 1998 |
Commentary: Another piece of the Alzheimer's jigsaw.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1999 |
Science commentary: rational drug design for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 1999 |
The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats.
Topics: Animals; Carbamates; Cholinesterase Inhibitors; Conditioning, Operant; Dose-Response Relationship, Drug; Male; Memory; Neuroprotective Agents; Phenylcarbamates; Rats; Reaction Time; Rivastigmine; Scopolamine | 1999 |
Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Topics: Acetylcholine; Acetylcholinesterase; Administration, Oral; Animals; Brain; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Extracellular Space; Hippocampus; Indans; Male; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Quality of Life; Rivastigmine | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Practice Guidelines as Topic; Rivastigmine | 1999 |
[Alzheimer disease: efficacy and tolerance of rivastagmine].
Topics: Aged; Alzheimer Disease; Carbamates; Double-Blind Method; Humans; Multicenter Studies as Topic; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 1999 |
Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Topics: Acetylcholinesterase; Adolescent; Adult; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Feasibility Studies; Humans; Male; Phenylcarbamates; Rivastigmine | 1999 |
Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.
Topics: Animals; Benzazepines; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Electrochemistry; Extracellular Space; Indans; Male; Microdialysis; Nootropic Agents; Peripheral Nervous System; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 1999 |
Effect of rivastigmine on scopolamine-induced memory impairment in rats.
Topics: Animals; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Drug Therapy, Combination; Hippocampus; Male; Maze Learning; Memory; Muscarinic Antagonists; Muscle, Skeletal; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Tacrine | 1999 |
New drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Donepezil; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Tacrine | 1999 |
Rivastigmine: a review.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 1999 |
Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits.
Topics: Animals; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Intraocular Pressure; Male; Ocular Hypertension; Phenylcarbamates; Rabbits; Rivastigmine; Time Factors; Tonometry, Ocular | 2000 |
Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
Topics: Alzheimer Disease; Carbamates; Clinical Trials as Topic; Humans; Neuroprotective Agents; Patient Selection; Phenylcarbamates; Rivastigmine | 2000 |
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Topics: Administration, Oral; Alzheimer Disease; Animals; Benzazepines; Brain; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Indans; Learning; Male; Memory; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 2000 |
Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats.
Topics: Animals; Brain; Carbamates; Cholinesterase Inhibitors; Cholinesterases; Female; Male; Memory; Memory Disorders; Muscarinic Antagonists; Muscle, Skeletal; Myocardium; Orchiectomy; Ovariectomy; Phenylcarbamates; Physostigmine; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Sex Factors | 2000 |
Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Comorbidity; Cytochrome P-450 Enzyme System; Data Interpretation, Statistical; Drug Interactions; Female; Humans; Male; Phenylcarbamates; Polypharmacy; Prospective Studies; Randomized Controlled Trials as Topic; Rivastigmine | 2000 |
The effect of rivastigmine on sleep in elderly healthy subjects.
Topics: Aged; Aging; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Phenylcarbamates; Reference Values; Rivastigmine; Sleep, REM | 2000 |
In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus.
Topics: Acetylcholine; Animals; Carbamates; Cholinesterase Inhibitors; Dopamine; gamma-Aminobutyric Acid; Hippocampus; Male; Norepinephrine; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Serotonin | 2000 |
New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Humans; Mental Disorders; Parasympathetic Nervous System; Phenylcarbamates; Rivastigmine | 2000 |
FDA approves new cholinesterase inhibitor for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; United States; United States Food and Drug Administration | 2000 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dystonia; Female; Humans; Indans; Memory Disorders; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Posture; Psychomotor Agitation; Risperidone; Rivastigmine; Syndrome | 2000 |
Third drug to treat Alzheimer's approved.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Drug Approval; Humans; Phenylcarbamates; Rivastigmine | 2000 |
Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Dose-Response Relationship, Drug; Esophageal Diseases; Female; Follow-Up Studies; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Rupture, Spontaneous; Syndrome | 2000 |
Rivastigmine (Exelon) for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine; Tacrine | 2000 |
Alzheimer's disease: translating neurochemical insights into clinical benefits.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Magnetic Resonance Imaging; Phenylcarbamates; Rivastigmine; Treatment Outcome; Trichlorfon | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine | 2000 |
Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat.
Topics: Animals; Body Temperature; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Hypothermia; Indans; Lacrimal Apparatus; Male; Phenylcarbamates; Piperidines; Rats; Rivastigmine; Saliva; Tacrine; Tremor; Trichlorfon | 2000 |
A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Lewy Body Disease; Male; Middle Aged; Phenylcarbamates; Polysomnography; Rivastigmine; Sleep Wake Disorders; Treatment Outcome | 2000 |
Cholinesterase inhibitors: expanding applications.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Phenylcarbamates; Rivastigmine | 2000 |
Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Caregivers; Cognition; Cost of Illness; Delivery of Health Care; Humans; Phenylcarbamates; Placebos; Rivastigmine; Treatment Outcome | 2000 |
Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Delirium; Female; Humans; Muscarinic Antagonists; Phenylcarbamates; Rivastigmine; Scopolamine | 2001 |
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost Savings; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2000 |
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Animals; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; In Vitro Techniques; Indans; Inhibitory Concentration 50; Male; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rivastigmine; Tacrine; Time Factors | 2000 |
Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.
Topics: Carbamates; Esophageal Diseases; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Rupture, Spontaneous | 2001 |
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep | 2001 |
Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.
Topics: Alzheimer Disease; Animals; Arginine; Aspartic Acid; Carbamates; Cholinesterase Inhibitors; Citrulline; Cyclic N-Oxides; Dose-Response Relationship, Drug; Excitatory Amino Acids; Extracellular Space; Glutamic Acid; Hippocampus; Male; Microdialysis; Neurons; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Synaptic Transmission; Taurine | 2001 |
Medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Donepezil; Estrogen Replacement Therapy; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Rivastigmine in the treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long-Term Care; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2001 |
Featured CME topic: dementia. Medication update.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Contraindications; Donepezil; Drug Interactions; Ergoloid Mesylates; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plants, Medicinal; Rivastigmine | 2001 |
Adverse reactions to rivastigmine in three cases of dementia.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Humans; Irritable Mood; Male; Phenylcarbamates; Rivastigmine; Treatment Failure | 2001 |
Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Protein Isoforms; Rivastigmine; Time Factors | 2001 |
Acetylcholinesterase inhibitor SDZ ENA 713 (Rivastigmine) increases brain pyrrolidone carboxyl peptidase activity.
Topics: Animals; Behavior, Animal; Brain; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Enzyme Activation; Male; Mice; Mice, Inbred BALB C; Phenylcarbamates; Prefrontal Cortex; Pyroglutamyl-Peptidase I; Rivastigmine; Synaptosomes | 2001 |
Maintaining functional and behavioral abilities in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Treatment Outcome | 2001 |
Erythematous maculopapular eruption due to rivastigmine therapy.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Parapsoriasis; Phenylcarbamates; Rivastigmine | 2001 |
Rivastagmine-induced agitation following transient recollection of autobiographical memory.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Phenylcarbamates; Psychomotor Agitation; Rivastigmine | 2001 |
Testosterone mediates sex difference in hypothermia and cholinesterase inhibition by rivastigmine.
Topics: Animals; Body Temperature; Carbamates; Cholinesterase Inhibitors; Female; Male; Orchiectomy; Phenylcarbamates; Pilocarpine; Rats; Rats, Sprague-Dawley; Rivastigmine; Sex Characteristics; Testosterone | 2001 |
Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Cognition; Female; Humans; Lewy Body Disease; Male; Middle Aged; Phenylcarbamates; Psychomotor Agitation; Rivastigmine; Sleep; Treatment Outcome | 2001 |
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Patient Dropouts; Phenylcarbamates; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Treatment Outcome | 2002 |
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Confidence Intervals; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Rivastigmine | 2001 |
Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Animals; Brain; Carbamates; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Inhibitory Concentration 50; Mice; Phenylcarbamates; Rats; Rivastigmine; Structure-Activity Relationship | 2002 |
Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.
Topics: Acetylcholinesterase; Animals; Binding Sites; Carbamates; Cholinesterase Inhibitors; Circular Dichroism; Crystallography, X-Ray; Drosophila melanogaster; Enzyme Activation; Kinetics; Neuroprotective Agents; Phenylcarbamates; Protein Conformation; Rivastigmine; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Torpedo | 2002 |
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Treatment Outcome | 2002 |
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome; United Kingdom | 2002 |
Rivastigmin and impaired motor function.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Catatonia; Dyskinesia, Drug-Induced; Female; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Patient Care Team; Phenylcarbamates; Rivastigmine | 2002 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capecitabine; Carbamates; Ceftriaxone; Clonidine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Ethacridine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Indapamide; Isotretinoin; Isoxazoles; Leflunomide; Male; Middle Aged; Nelfinavir; Phenylcarbamates; Rivastigmine; Salicylates; Severity of Illness Index; Sulfonamides; Thiophenes | 2002 |
Prolonged QT interval with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Evaluation Studies as Topic; Event-Related Potentials, P300; Female; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Reaction Time; Rivastigmine; Sensitivity and Specificity; Severity of Illness Index; Tacrine | 2001 |
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
Topics: Acetylcholine; Aging; Animals; Body Weight; Brain; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Administration Schedule; Hippocampus; Indans; Male; Muscarinic Antagonists; Phenylcarbamates; Piperidines; Pirenzepine; Rats; Rats, Inbred F344; Rivastigmine; Trichlorfon | 2002 |
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Brain; Carbamates; Case-Control Studies; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Follow-Up Studies; Humans; Indans; Male; Phenylcarbamates; Piperidines; Radiopharmaceuticals; Rivastigmine; Technetium Tc 99m Exametazime; Time Factors; Tomography, Emission-Computed, Single-Photon | 2002 |
Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibitors; Electric Stimulation; Electromagnetic Phenomena; Evoked Potentials, Motor; Female; Humans; Linear Models; Male; Middle Aged; Motor Cortex; Multivariate Analysis; Neural Inhibition; Phenylcarbamates; Reaction Time; Rivastigmine | 2002 |
Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Antibodies, Monoclonal; Basal Nucleus of Meynert; Carbamates; Cerebral Cortex; Choline O-Acetyltransferase; Cholinergic Fibers; Cholinesterase Inhibitors; Disease Models, Animal; Immunohistochemistry; Immunotoxins; Male; N-Glycosyl Hydrolases; Neural Inhibition; Neural Pathways; Neurons; Phenylcarbamates; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Reflex, Startle; Ribosome Inactivating Proteins, Type 1; Rivastigmine; Saporins; Treatment Outcome | 2002 |
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Hallucinations; Humans; Male; Parkinson Disease; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2002 |
Fatal aspiration pneumonia during transition from donepezil to rivastigmine.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Fatal Outcome; Humans; Indans; Male; Phenylcarbamates; Piperidines; Pneumonia, Aspiration; Rivastigmine | 2002 |
The impact of journal advertisements on prescribers of cholinesterase inhibitors.
Topics: Advertising; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publishing; Random Allocation; Rivastigmine | 2002 |
Electroconvulsive therapy in a patient receiving rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Phenylcarbamates; Rivastigmine; Safety; Treatment Outcome | 2002 |
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Attention; Brain Mapping; Carbamates; Cerebral Cortex; Cholinergic Fibers; Cholinesterase Inhibitors; Female; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Mental Recall; Nerve Net; Neuroprotective Agents; Neuropsychological Tests; Pattern Recognition, Visual; Phenylcarbamates; Prefrontal Cortex; Rivastigmine | 2002 |
Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Reproducibility of Results; Research Design; Rivastigmine | 2002 |
Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.
Topics: Acetylcholinesterase; Alkaloids; Animals; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Hippocampus; Indans; Isoenzymes; Kinetics; Male; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rats, Sprague-Dawley; Rivastigmine; Sesquiterpenes; Tacrine | 2002 |
Rivastigmine in the treatment of Huntington's disease.
Topics: Carbamates; Cholinesterase Inhibitors; Humans; Huntington Disease; Phenylcarbamates; Rivastigmine | 2002 |
Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry.
Topics: Calibration; Carbamates; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Humans; Phenylcarbamates; Reference Standards; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity | 2003 |
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Carbamates; Cholinesterase Inhibitors; Drug Therapy, Combination; Humans; Levodopa; Lewy Body Disease; Male; Neuroprotective Agents; Olanzapine; Phenylcarbamates; Pirenzepine; Risperidone; Rivastigmine; Treatment Outcome | 2003 |
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Product Surveillance, Postmarketing; Rivastigmine; Surveys and Questionnaires; Tacrine; Treatment Outcome | 2003 |
[Ethical aspects of anti-Alzheimer drugs: experiences of caregivers].
Topics: Aged; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cognition; Decision Making; Ethics, Clinical; Female; Humans; Male; Netherlands; Phenylcarbamates; Quality of Life; Rivastigmine | 2002 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihydroergotoxine; Donepezil; Family Practice; Female; Follow-Up Studies; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nimodipine; Nootropic Agents; Phenylcarbamates; Piperidines; Piracetam; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Time Factors; Vasodilator Agents | 2002 |
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Topics: Allosteric Regulation; Animals; Carbamates; Cells, Cultured; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Mice; Neurons; Phenylcarbamates; Piperidines; Receptors, Muscarinic; Receptors, Nicotinic; Recombinant Fusion Proteins; Rivastigmine; Tacrine; Trichlorfon | 2003 |
[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety Disorders; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Female; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 2003 |
Surprising discovery with Alzheimer's medication.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Crystallography, X-Ray; Humans; Phenylcarbamates; Rivastigmine | 2003 |
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Topics: Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Lewy Body Disease; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2003 |
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Topics: Carbamates; Cholinesterase Inhibitors; Hospitalization; Humans; Lewy Body Disease; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Time Factors; Treatment Outcome | 2003 |
Rivastigmine and QT interval prolongation.
Topics: Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2003 |
Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Carbamates; Cholinesterase Inhibitors; Colitis, Ulcerative; Delirium; Humans; Male; Parkinson Disease; Phenylcarbamates; Postoperative Complications; Rivastigmine | 2003 |
Rivastigmine in the treatment of alcohol-induced persisting dementia.
Topics: Alcohol-Induced Disorders, Nervous System; Alzheimer Disease; Carbamates; Central Nervous System Depressants; Cholinesterase Inhibitors; Ethanol; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine | 2003 |
Comparative study of donepezil and rivastigmine.
Topics: Carbamates; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2003 |
Influence of cholinergic circuitries in generation of high-frequency somatosensory evoked potentials.
Topics: Acetylcholine; Adult; Brain Mapping; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Electric Stimulation; Electroencephalography; Evoked Potentials, Somatosensory; Humans; Male; Median Nerve; Neural Pathways; Phenylcarbamates; Reaction Time; Rivastigmine; Scalp; Somatosensory Cortex | 2003 |
Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
Topics: Aged; Aggression; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia, Vascular; Female; Geriatric Assessment; Humans; Neuroprotective Agents; Phenylcarbamates; Psychomotor Agitation; Rivastigmine; Sexual Behavior; Time Factors | 2003 |
Editorial comment--How to treat vascular dementia?
Topics: Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2003 |
Rivastigmine blocks voltage-activated K+ currents in dissociated rat hippocampal neurons.
Topics: Animals; Carbamates; Dose-Response Relationship, Drug; Hippocampus; Male; Membrane Potentials; Neurons; Phenylcarbamates; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Rats; Rats, Wistar; Rivastigmine | 2003 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Edrophonium; Humans; In Vitro Techniques; Phenylcarbamates; Physostigmine; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2004 |
No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
Topics: Aged; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Failure; Treatment Outcome | 2003 |
Thalamic lesions in vascular dementia: low sensitivity of fluid-attenuated inversion recovery (FLAIR) imaging.
Topics: Aged; Aged, 80 and over; Carbamates; Clinical Trials, Phase III as Topic; Dementia, Vascular; Humans; Magnetic Resonance Imaging; Middle Aged; Multicenter Studies as Topic; Phenylcarbamates; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Rivastigmine; Sensitivity and Specificity; Single-Blind Method; Thalamus | 2004 |
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine | 2003 |
Nightmares without atonia as an early symptom of diffuse Lewy bodies disease.
Topics: Aged; Atrophy; Carbamates; Cholinesterase Inhibitors; Dreams; Fatal Outcome; Humans; Immunohistochemistry; Lewy Body Disease; Magnetic Resonance Spectroscopy; Male; Neurons; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Substantia Nigra; Tomography, X-Ray Computed | 2003 |
Italian drug policy: ethical aims of essential assistance levels.
Topics: Anticholesteremic Agents; Atorvastatin; Carbamates; Cholinesterase Inhibitors; Drug Costs; Drugs, Essential; Formularies as Topic; Health Care Costs; Health Care Rationing; Health Policy; Heptanoic Acids; Humans; Insurance, Health, Reimbursement; Italy; Medical Assistance; National Health Programs; Phenylcarbamates; Pyrroles; Rivastigmine | 2003 |
Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cohort Studies; Cost of Illness; Cost Savings; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Health Expenditures; Humans; Institutionalization; Mental Status Schedule; New York City; Phenylcarbamates; Prospective Studies; Psychometrics; Rivastigmine | 2003 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine; Stroke; Terminology as Topic | 2004 |
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; Centrifugation, Density Gradient; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Isoenzymes; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parietal Lobe; Phenylcarbamates; Rivastigmine; Tacrine; Time | 2004 |
Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease.
Topics: Afferent Pathways; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinergic Fibers; Cholinesterase Inhibitors; Evoked Potentials, Motor; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; N-Methylaspartate; Nerve Net; Neural Inhibition; Phenylcarbamates; Reaction Time; Rivastigmine; Sensory Thresholds; Signal Processing, Computer-Assisted; Transcranial Magnetic Stimulation | 2004 |
Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Models, Statistical; Multicenter Studies as Topic; Phenylcarbamates; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Treatment Outcome | 2004 |
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Databases, Factual; Drug Utilization; Female; Humans; Male; Phenylcarbamates; Risk Assessment; Rivastigmine; Sex Characteristics | 2004 |
[Acetylcholinesterase inhibitors].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Galantamine; Humans; Phenylcarbamates; Rivastigmine | 2003 |
Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Topics: Acetylcholine; Autistic Disorder; Brain; Carbamates; Child; Child Development Disorders, Pervasive; Child, Preschool; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Language Development Disorders; Male; Neuropsychological Tests; Pattern Recognition, Visual; Personality Assessment; Phenylcarbamates; Rivastigmine; Social Behavior; Treatment Outcome; Vocabulary | 2004 |
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Fasciculation; Indans; Male; Neurons; Phenylcarbamates; Piperidines; Rats; Rats, Sprague-Dawley; Rivastigmine; Sesquiterpenes; Up-Regulation | 2004 |
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galantamine; Hallucinations; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Agitation; Rivastigmine; Social Behavior | 2004 |
Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain.
Topics: Animals; Blood Pressure; Brain; Brain Chemistry; Carbamates; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Dementia, Vascular; Hypertension; Male; Membrane Transport Proteins; Phenylcarbamates; Rats; Rats, Inbred SHR; Rats, Wistar; Rivastigmine; Vesicular Acetylcholine Transport Proteins; Vesicular Transport Proteins | 2004 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2004 |
Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.
Topics: Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Delirium; Female; Hospitalization; Humans; Male; Middle Aged; Phenylcarbamates; Retrospective Studies; Risk Factors; Rivastigmine | 2004 |
[Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Delirium; Haloperidol; Hospitalization; Humans; Male; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2004 |
The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Topics: Animals; Basal Ganglia; Behavior, Animal; Carbamates; Cholinesterase Inhibitors; Dopamine; Hippocampus; Hyperkinesis; Indans; Levodopa; Lewy Body Disease; Male; Monoamine Oxidase Inhibitors; Motor Activity; Muscarinic Antagonists; Norepinephrine; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Serotonin; Time Factors; Tranylcypromine; Tryptophan | 2005 |
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Humans; Indans; Inhibition, Psychological; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase Inhibitors; Phenylcarbamates; Rivastigmine; Selegiline | 2007 |
Microcalorimetric study of the inhibition of butyrylcholinesterase by carbamates.
Topics: Animals; Butyrylcholinesterase; Calorimetry; Carbamates; Cholinesterase Inhibitors; Horses; Kinetics; Neostigmine; Phenylcarbamates; Physostigmine; Rivastigmine | 2008 |
Novel carbamate cholinesterase inhibitors that release biologically active amines following enzyme inhibition.
Topics: Administration, Oral; Amnesia; Amphetamines; Animals; Biogenic Amines; Carbamates; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Phenylcarbamates; Rats; Rivastigmine | 2009 |
Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking.
Topics: Acetylcholinesterase; Animals; Binding Sites; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Electrophorus; Galantamine; Models, Molecular; Molecular Docking Simulation; Phenylcarbamates; Rivastigmine; Salicylanilides; Structure-Activity Relationship | 2012 |
Cholinergic Anti-Inflammatory Pathway Does Not Contribute to Prevention of Ulcerative Colitis by Novel Indoline Carbamates.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Carbamates; Cholinesterase Inhibitors; Colitis, Ulcerative; Colon; Indoles; Male; Mice; Rivastigmine | 2017 |
New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators.
Topics: Alzheimer Disease; Amidohydrolases; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cannabinoids; Carbamates; Chemistry, Pharmaceutical; Cholinergic Agents; Coumarins; Drug Design; Endocannabinoids; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Rats; Receptors, Cannabinoid; Receptors, Cholinergic; Rivastigmine | 2021 |